Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Developing and Validating Prognostic Models for Black women with Endometrial Cancer following Hysterectomy

Award Number: R00CA297013
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/13/2025
PERIOD OF PERFORMANCE END DATE: 04/30/2029

Group Awards By:

View Award Description

Developing and Validating Prognostic Models for Black women with Endometrial Cancer following Hysterectomy - Endometrial cancer (EC) incidence and mortality are rising rapidly in the U.S. Black women are experiencing the sharpest increase, with incidence and mortality rising 46% and 29%, respectively, from 1999–2015. While the 5-year survival for EC overall is 80%, for Black patients it is only 63%. This is due, in part, to the more frequent diagnosis of aggressive non-endometrioid tumor subtypes in Black women (~35% vs ~17% non-Black). Primary staging and treatment for EC is surgical hysterectomy with bilateral salpingo-oophorectomy; several adjuvant therapies allow for the tailoring of post-surgical treatment, requiring careful balancing of prognosis/recurrence risks with adverse effects of therapy to improve outcomes and avoid mistreatment. Black women are more commonly diagnosed with these aggressive histologic subtypes not amenable to surgical resection alone. There are no prognostic tools to inform discussion of adjuvant therapies for Black women diagnosed with EC. This Early K99/R00 application leverages years of NIH funding and collaboration to develop and externally validate prognostic tools for Black women with EC post-hysterectomy. This research will inform discussion of tailored adjuvant therapies in clinical settings. It is foundational for Dr. Peeri to achieve research independence focused on creating clinical decision-making tools for all populations. Our specific aims are to: 1A) build a robust prognostic tool tailored for Black EC patients using readily available clinical and epidemiologic factors to predict survival 3- and 5-years post-hysterectomy, and to externally validate this tool in the MSK Cohort; 1B) compare model performance for Black patients with an established model developed primarily in White women; 1C) develop an easy-to-use survival nomogram web-based tool for clinician and patient use; 2A) assess the utility of adding existing TCGA molecular subtypes to our prognostic tool for Black women and externally validate in the MSK cohort; and 2B) use established clinical tools in our population as a point of reference for evaluating the performance of our model; 3) build biomarker-based prognostic tools to predict overall survival at 3- and 5-years post-hysterectomy in 3A) Black women, expanding upon the prognostic tools developed in Aim 1, and 3B) White women, expanding on an established tool. The training goals are to: 1) receive training in rigorous prognostic model development and validation methods; 2) receive training in cancer genomics including advanced methods for whole-exome sequence data; 3) expand knowledge of biomarkers of clinical significance and machine-learning methods for model development; and 4) lay a foundation to support an independent research career in cancer health disparities. Ultimately, this proposal will advance the career of a young investigator with a strong research background from postdoctoral fellow to independence.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $249,000 )
2026	2026	THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	001	3	9/16/2026	EXTENSION WITH OR WITHOUT FUNDS	$0
2026	2026	THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER	1515 HOLCOMBE BLVD	HOUSTON	TX	77030	HARRIS	USA	Cancer Treatment Research	000	3	9/2/2026	EXTENSION WITH OR WITHOUT FUNDS	$249,000
														Subtotal = $249,000

Grand Total All Awards = $249,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Developing and Validating Prognostic Models for Black women with Endometrial Cancer following Hysterectomy

Award Number: R00CA297013

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/13/2025

PERIOD OF PERFORMANCE END DATE: 04/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer